Dicerna Pharmaceuticals, Inc. DRNA was a big mover last session, as the company saw its shares rise more than 10% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company—as the stock is now up 53.6% in the past one-month time frame.
The company has seen four positive estimate revisions in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few weeks, suggesting that more solid trading could be ahead for Dicerna Pharmaceuticals. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.
Dicerna Pharmaceuticals currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Dicerna Pharmaceuticals, Inc. Price
Dicerna Pharmaceuticals, Inc. price | Dicerna Pharmaceuticals, Inc. Quote
Investors interested in the Medical – Biomedical and Genetics industry may consider Alkermes plc ALKS, which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is DRNA going up? Or down? Predict to see what others think:Up or Down
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers “Most Likely for Early Price Pops.”
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.6% per year. So be sure to give these hand-picked 7 your immediate attention.
See 7 handpicked stocks now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Dicerna Pharmaceuticals, Inc. (DRNA) : Free Stock Analysis Report
Alkermes plc (ALKS) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research